Rationale and design for the study of recombinant human hepatocyte growth factor plasmid in the treatment of patients with chronic limb-threatening ischemia (HOPE CLTI): Randomized, placebo-controlled, double-blind, III clinical trials

Di, X; Liu, CW; Ni, L; Ye, W; Rong, ZH; Zhang, R; Niu, S; Li, FS; Zheng, YH; Han, CQ; Liu, Y

Liu, CW (通讯作者),Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Vasc Surg, Beijing, Peoples R China.;Liu, CW (通讯作者),Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Vasc Surg, 1 Shuaifuyuan, Beijing 100730, Peoples R China.

AMERICAN HEART JOURNAL, 2022; 254 (): 88

Abstract

Background Although patients with CLTI have benefited from the rapid development of endovascular techniques, many patients are considered unsuitable f......

Full Text Link